

#### Consumer & Retail Personal Products

Equity - India

Neutral						
Target price (INR) 190.00 Share price (INR) 205.95 Potential return (%) -6.4						
Performance	)	1M	3M	12M		
Absolute (%) Relative^ (%)		7.7 7.1	17.2 13.9	57.6 32.1		
Index^	BOMBA	SE SI	ENSITIVE	INDEX		
RIC Bloomberg				ABU.BO BUR IN		
Market cap (I Market cap (I	,		1	3,799 78,918		
Enterprise va	lue (INRm)		1	77,539		

Note: (V) = volatile (please see disclosure appendix)

22

#### 22 July 2010

Free float (%)

#### Percy Panthaki\*

Analyst
HSBC Securities and Capital Markets
(India) Private Limited
+9122 2268 1240
percypanthaki@hsbc.co.in

View HSBC Global Research at: <a href="http://www.research.hsbc.com">http://www.research.hsbc.com</a>

\*Employed by a non-US affiliate of HSBC Securities (USA) Inc, and is not registered/qualified pursuant to FINRA regulations

Issuer of report: HSBC Securities and

Capital Markets
(India) Private Limited

## Disclaimer & Disclosures

This report must be read with the disclosures and the analyst certifications in the Disclosure appendix, and with the Disclaimer, which forms part of it

### Dabur India (DABUR)

N: Potential Hobi Kozmetic acquisition small but positive

- Newspaper reports Dabur in talks to acquire Hobi Kozmetic, a Turkish personal products company
- Acquisition could add c4% to revenues and be value accretive / EPS accretive by c1-2% in the first year
- We maintain our Neutral rating and our PE-based target price of INR190

*Economic Times* reports that Dabur is in talks to acquire Hobi Kozmetic, a Turkish personal products company. Dabur will not confirm that it is close to finalising an acquisition of Hobi Kozmetic, drawing attention to the fact that it is in talks with more than one company (source: Reuters).

**Could be strategically positive...** Hobi Kozmetic makes hairstyling, hair-care, skincare and bath and shower products under the brand names Hobby and New Era and it has a presence in more than 30 countries. Our channel checks indicate annual revenues of cINR1.3b, c4% of Dabur's existing revenues. Hobi Kozmetic would give Dabur a presence in Turkey and help take Hobi Kozmetic products into its existing operations in the MENA region.

...and possibly value / EPS accretive. Recent international acquisitions of this type have taken place at c2x sales. Assuming a net profit margin of 15% for Hobi, we estimate acquisition of Hobi Kozmetic could be value / EPS accretive by c1-2%. The acquisition may have to be financed by debt, but at 2x sales we estimate the purchase price would be just c20% of shareholders' funds, so gearing should not be a problem.

**No change to our valuation – remain Neutral.** We value Dabur on 24x FY12e EPS. Dabur's PE has averaged 22x over the last three years, within a band of 13-28x. We believe that given the better quality of growth – strong volumes, and almost all categories growing – Dabur stock deserves a premium of 10% over its historical average.

Dabur: Snapshot Financials (INRm)										
Year to Mar	Sales	у-о-у	EBIT	у-о-у	Net profit	у-о-у	EPS (INR)	PE	ROE	ROA
FY09	28,054	18.8%	4,212	14.7%	3,912	17.1%	4.51	45.7x	54.5%	24.4%
FY10e	33,657	20.0%	5.773	37.0%	5.035	28.7%	5.79	35.6x	50.3%	24.7%
FY11e	39,038	16.0%	6.675	15.6%	5,916	17.5%	6.80	30.3x	44.0%	24.0%
FY12e	45,261	15.9%	7,992	19.7%	6,963	17.7%	8.01	25.7x	41.1%	23.5%

Source: Company, HSBC

Vote for the World's Local Broker - www.asiamoney.com/polls




#### Financials & valuation

Financial statements							
Year to	03/2009a	03/2010e	03/2011e	03/2012e			
Profit & loss summary (INRm)							
Revenue	28,054	33,657	39,038	45,261			
EBITDA	4,705	6,330	7,340	8,676			
Depreciation & amortisation	-492	-557	-664	-684			
Operating profit/EBIT	4,212	5,773	6,675	7,992			
Net interest	-232	-132	-139	-140			
PBT	4,448	6,028	7,147	8,462			
HSBC PBT	4,448	6,028	7,147	8,462			
Taxation	-540	-985	-1,236	-1,506			
Net profit	3,912	5,035	5,916	6,963			
HSBC net profit	3,912	5,035	5,916	6,963			
Cash flow summary (INRm	)						
Cash flow from operations	3,420	4,077	5,650	6,687			
Capex	-1,388	-4,500	-400	-400			
Cash flow from investment	-2,352	-2,643	10	-10			
Dividends	-1,517	-2,158	-2,492	-2,931			
Change in net debt	566	-170	-3,176	-3,756			
FCF equity	1,996	-423	5,250	6,287			
Balance sheet summary (I	NRm)						
Intangible fixed assets	0	0	0	0			
Tangible fixed assets	5,592	9,594	9,330	9,045			
Current assets	9,508	10,928	15,567	20,945			
Cash & others	1,484	1,677	4,877	8,656			
Total assets	18,891	22,784	27,359	32,673			
Operating liabilities	7,064	7,155	8,280	9,536			
Gross debt	2,276	2,299	2,322	2,345			
Net debt	792	621	-2,555	-6,311			
Shareholders funds	8,188	11,832	15,056	18,849			
Invested capital	6,551	11,690	11,740	11,798			

Ratio, growth and per share analysis							
Year to	03/2009a	03/2010e	03/2011e	03/2012e			
Y-o-y % change							
Revenue	18.8	20.0	16.0	15.9			
EBITDA	14.9	34.5	16.0	18.2			
Operating profit	14.7	37.0	15.6	19.7			
PBT	15.7	35.5	18.6	18.4			
HSBC EPS	17.8	28.4	17.5	17.7			
Ratios (%)							
Revenue/IC (x)	4.8	3.7	3.3	3.8			
ROIC	62.6	51.8	46.0	54.7			
ROE	54.5	50.3	44.0	41.1			
ROA	24.4	24.7	24.0	23.5			
EBITDA margin	16.8	18.8	18.8	19.2			
Operating profit margin	15.0	17.2	17.1	17.7			
EBITDA/net interest (x)	20.3	48.1	53.0	62.0			
Net debt/equity	9.6	5.2	-16.9	-33.4			
Net debt/EBITDA (x)	0.2	0.1	-0.3	-0.7			
CF from operations/net debt	432.1	656.3					
Per share data (INR)							
EPS reported (fully diluted)	4.51	5.79	6.80	8.01			
HSBC EPS (fully diluted)	4.51	5.79	6.80	8.01			
DPS	1.75	2.25	2.65	3.11			
Book value	9.49	13.61	17.31	21.67			

Valuation data						
Year to	03/2009a	03/2010e	03/2011e	03/2012e		
EV/sales	6.3	5.3	4.5	3.8		
EV/EBITDA	37.5	28.0	23.7	19.6		
EV/IC	26.9	15.2	14.8	14.4		
PE*	45.7	35.6	30.3	25.7		
P/Book value	21.7	15.1	11.9	9.5		
FCF yield (%)	1.1	-0.2	3.0	3.6		
Dividend yield (%)	0.8	1.1	1.3	1.5		

Note: \* = Based on HSBC EPS (fully diluted)



Note: price at close of 21 Jul 2010



#### Acquisition of Hobi Kozmetic would be small, but positive

We think acquisition of Hobi Kozmetic by Dabur would allow Dabur to strengthen its MENA presence and cross-pollinate products across geographies. Although small in terms of sales volume, it could give Dabur a foothold in Turkey and bring synergies to the top and bottom line.

Analysis of potential Hobi Kozmetic acquisition – Value / EPS accretive by c1-2% (annualised, 1st year of operation
---

	INRm
Sales in FY10	1300
Sales in FY11e (15% growth assumed)	1495
Net margin	15%
Net profit FY11e	224.25
Acquisition price (2x FY10 sales)	2600
Implied PE of acquisition at FY11 earnings	11.5942
Fair value (@20x PE)	4485
Value accretion	1885
Value accretion per share	2.166667
Value accretion %	1.1%
Debt	2600
Post-tax cost of debt	5%
Interest paid	130
Net profit accretion	94.25
EPS accretion	0.108333
EPS accretion %	1.6%

Source: HSBC

In the table below, we calculate value accretion at 1.1% and EPS accretion at 1.6% (annualised). As we assume the debt would be paid off by the end of the first year, from the second year onwards EPS accretion could be higher at nearly 4%. We note that synergies could add to this number in the long run.

The *Economic Times* also states that "Dabur CEO Sunil Duggal had last month told ET that the company was looking to buy one mid-sized or two small-sized companies every year. Middle East, sub-Saharan Africa, Turkey and Indonesia as key markets, adding that hair, oral and skin care would be its focus areas". We would view these as positive as and when they happen provided that they are at the right price and synergistic either in terms of product or geography.

#### Valuation

We value Dabur on a PE of 24x FY12e EPS, or a target price of INR190. Dabur stock's PE has averaged 22x over the last three years, within a band of 13-28x. We believe that given the better quality of growth – strong volumes, and almost all categories participating in the growth – Dabur stock deserves a premium of 10% over its historical average. We maintain our Neutral rating on the stock.

**Downside risks**: 1) A grim macroeconomic environment or an inflationary situation that may impact consumer spending and affect volume growth for FMCG companies; 2) raw material cost inflation higher than estimated, which may adversely impact margins; 3) retail losses deeper than we estimate; 4) competitive pressures are increasing in the FMCG industry, which could affect revenue or costs or both by requiring higher ad spend than previously estimated; 5) price competition may lead to lower unit realisations and margin compression; 6) synergies expected with FCPL do not flow through.

**Upside risks**: Price increases being higher than necessary to offset cost inflation; PE multiple expansion on the back of entry into new categories; value-accretive acquisitions.



# Disclosure appendix

#### **Analyst Certification**

The following analyst(s), economist(s), and/or strategist(s) who is(are) primarily responsible for this report, certifies(y) that the opinion(s) on the subject security(ies) or issuer(s) and/or any other views or forecasts expressed herein accurately reflect their personal view(s) and that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report: Percy Panthaki

#### Important disclosures

#### Stock ratings and basis for financial analysis

HSBC believes that investors utilise various disciplines and investment horizons when making investment decisions, which depend largely on individual circumstances such as the investor's existing holdings, risk tolerance and other considerations. Given these differences, HSBC has two principal aims in its equity research: 1) to identify long-term investment opportunities based on particular themes or ideas that may affect the future earnings or cash flows of companies on a 12 month time horizon; and 2) from time to time to identify short-term investment opportunities that are derived from fundamental, quantitative, technical or event-driven techniques on a 0-3 month time horizon and which may differ from our long-term investment rating. HSBC has assigned ratings for its long-term investment opportunities as described below.

This report addresses only the long-term investment opportunities of the companies referred to in the report. As and when HSBC publishes a short-term trading idea the stocks to which these relate are identified on the website at www.hsbcnet.com/research. Details of these short-term investment opportunities can be found under the Reports section of this website.

HSBC believes an investor's decision to buy or sell a stock should depend on individual circumstances such as the investor's existing holdings and other considerations. Different securities firms use a variety of ratings terms as well as different rating systems to describe their recommendations. Investors should carefully read the definitions of the ratings used in each research report. In addition, because research reports contain more complete information concerning the analysts' views, investors should carefully read the entire research report and should not infer its contents from the rating. In any case, ratings should not be used or relied on in isolation as investment advice.

#### Rating definitions for long-term investment opportunities

#### Stock ratings

HSBC assigns ratings to its stocks in this sector on the following basis:

For each stock we set a required rate of return calculated from the risk free rate for that stock's domestic, or as appropriate, regional market and the relevant equity risk premium established by our strategy team. The price target for a stock represents the value the analyst expects the stock to reach over our performance horizon. The performance horizon is 12 months. For a stock to be classified as Overweight, the implied return must exceed the required return by at least 5 percentage points over the next 12 months (or 10 percentage points for a stock classified as Volatile\*). For a stock to be classified as Underweight, the stock must be expected to underperform its required return by at least 5 percentage points over the next 12 months (or 10 percentage points for a stock classified as Volatile\*). Stocks between these bands are classified as Neutral.

Our ratings are re-calibrated against these bands at the time of any 'material change' (initiation of coverage, change of volatility status or change in price target). Notwithstanding this, and although ratings are subject to ongoing management review, expected returns will be permitted to move outside the bands as a result of normal share price fluctuations without necessarily triggering a rating change.

\*A stock will be classified as volatile if its historical volatility has exceeded 40%, if the stock has been listed for less than 12 months (unless it is in an industry or sector where volatility is low) or if the analyst expects significant volatility. However,

4




stocks which we do not consider volatile may in fact also behave in such a way. Historical volatility is defined as the past month's average of the daily 365-day moving average volatilities. In order to avoid misleadingly frequent changes in rating, however, volatility has to move 2.5 percentage points past the 40% benchmark in either direction for a stock's status to change.

#### Rating distribution for long-term investment opportunities

#### As of 22 July 2010, the distribution of all ratings published is as follows:

Overweight (Buy)	52%	(20% of these provided with Investment Banking Services)
Neutral (Hold)	35%	(18% of these provided with Investment Banking Services)
Underweight (Sell)	13%	(19% of these provided with Investment Banking Services)

#### Share price and rating changes for long-term investment opportunities



Recommendation & price target history					
From	То	Date			
Overweight (V)	Overweight	24 July 2007			
Overweight	Neutral (V)	31 October 2008			
Neutral (V)	Overweight (V)	24 November 2008			
Overweight (V)	Neutral (V)	13 July 2009			
Neutral (V)	Overweight (V)	01 September 2009			
Overweight (V)	Overweight	18 January 2010			
Overweight	Neutral	16 April 2010			
Neutral	Neutral	09 July 2010			
Target Price	Value	Date			
Price 1	125.00	24 October 2007			
Price 2	118.00	16 May 2008			
Price 3	110.00	29 July 2008			
Price 4	94.50	31 October 2008			
Price 5	123.00	30 April 2009			
Price 6	137.00	15 June 2009			
Price 7	158.00	05 August 2009			
Price 8	180.00	26 October 2009			
Price 9	190.00	18 January 2010			

Source: HSBC



#### **HSBC & Analyst disclosures**

Disclosure checklist				
Company	Ticker	Recent price	Price Date	Disclosure
DABUR INDIA	DABU.BO	205.95	21-Jul-2010	2

Source: HSBC

- 1 HSBC\* has managed or co-managed a public offering of securities for this company within the past 12 months.
- 2 HSBC expects to receive or intends to seek compensation for investment banking services from this company in the next 3 months.
- 3 At the time of publication of this report, HSBC Securities (USA) Inc. is a Market Maker in securities issued by this company.
- 4 As of 30 June 2010 HSBC beneficially owned 1% or more of a class of common equity securities of this company.
- As of 31 May 2010, this company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of investment banking services.
- As of 31 May 2010, this company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of non-investment banking-securities related services.
- As of 31 May 2010, this company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of non-securities services.
- 8 A covering analyst/s has received compensation from this company in the past 12 months.
- 9 A covering analyst/s or a member of his/her household has a financial interest in the securities of this company, as detailed below.
- 10 A covering analyst/s or a member of his/her household is an officer, director or supervisory board member of this company, as detailed below.
- 11 At the time of publication of this report, HSBC is a non-US Market Maker in securities issued by this company and/or in securities in respect of this company

Analysts, economists, and strategists are paid in part by reference to the profitability of HSBC which includes investment banking revenues.

For disclosures in respect of any company mentioned in this report, please see the most recently published report on that company available at www.hsbcnet.com/research.

\* HSBC Legal Entities are listed in the Disclaimer below.

#### Additional disclosures

- 1 This report is dated as at 22 July 2010.
- 2 All market data included in this report are dated as at close 21 July 2010, unless otherwise indicated in the report.
- HSBC has procedures in place to identify and manage any potential conflicts of interest that arise in connection with its Research business. HSBC's analysts and its other staff who are involved in the preparation and dissemination of Research operate and have a management reporting line independent of HSBC's Investment Banking business. Information Barrier procedures are in place between the Investment Banking and Research businesses to ensure that any confidential and/or price sensitive information is handled in an appropriate manner.



# Disclaimer

\* Legal entities as at 31 January 2010

'UAE' HSBC Bank Middle East Limited, Dubai; 'HK' The Hongkong and Shanghai Banking Corporation Limited, Hong Kong; 'TW' HSBC Securities (Taiwan) Corporation Limited; 'CA' HSBC Securities (Canada) Inc, Toronto; HSBC Bank, Paris branch; HSBC France; 'DE' HSBC Trinkaus & Burkhardt AG, Dusseldorf; 000 HSBC Bank (RR), Moscow; 'IN' HSBC Securities and Capital Markets (India) Private Limited, Mumbai; 'JP' HSBC Securities (Japan) Limited, Tokyo; 'EG' HSBC Securities Egypt S.A.E., Cairo; 'CN' HSBC Investment Bank Asia Limited, Beijing Representative Office; The Hongkong and Shanghai Banking Corporation Limited, Singapore branch; The Hongkong and Shanghai Banking Corporation Limited, Seoul Securities Branch; The Hongkong and Shanghai Banking Corporation Limited, Seoul Branch; HSBC Securities (South Africa) (Pty) Ltd, Johannesburg; 'GR' HSBC Pantelakis Securities S.A., Athens; HSBC Bank plc, London, Madrid, Milan, Stockholm, Tel Aviv, 'US' HSBC Securities (USA) Inc, New York; HSBC Yatirim Menkul Degerler A.S., Istanbul; HSBC México, S.A., Institución de Banca Múltiple, Grupo Financiero HSBC, HSBC Bank Brasil S.A. - Banco Múltiplo, HSBC Bank Australia Limited, HSBC Bank Argentina S.A., HSBC Saudi Arabia Limited.

Issuer of report
HSBC Securities and Capital Markets
(India) Private Limited
Registered Office
52/60 Mehatma Gandhi Bood

52/60 Mahatma Gandhi Road Fort, Mumbai 400 001, India Telephone: +91 22 2267 4921 Fax: +91 22 2263 1983

Website: www.research.hsbc.com

This document has been issued by HSBC Securities and Capital Markets (India) Private Limited ("HSBC") for the information of its customers only. HSBC Securities and Capital Markets (India) Private Limited is regulated by the Securities and Exchange Board of India. If it is received by a customer of an affiliate of HSBC, its provision to the recipient is subject to the terms of business in place between the recipient and such affiliate. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. HSBC has based this document on information obtained from sources it believes to be reliable but which it has not independently verified; HSBC makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of the Research Division of HSBC only and are subject to change without notice. HSBC and its affiliates and/or their officers, directors and employees may have positions in any securities mentioned in this document (or in any related investment) and may from time to time add to or dispose of any such securities (or investment). HSBC and its affiliates may act as market maker or have assumed an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform investment banking or underwriting services for or relating to those companies and may also be represented in the supervisory board or any other committee of those companies. The information and opinions contained within the research reports are based upon publicly available information and rates of taxation applicable at the time of publication which are subject to change from time to time. Past performance is not necessarily a guide to future performance. The value of any investment or income may go down as well as up and you may not get back the full amount invested. Where an investment is denominated in a currency other than the local currency of the recipient of the research report, changes in the exchange rates may have an adverse effect on the value, price or income of that investment. In case of investments for which there is no recognised market it may be difficult for investors to sell their investments or to obtain reliable information about its value or the extent of the risk to which it is

HSBC Securities (USA) Inc. accepts responsibility for the content of this research report prepared by its non-US foreign affiliate. All U.S. persons receiving and/or accessing this report and wishing to effect transactions in any security discussed herein should do so with HSBC Securities (USA) Inc. in the United States and not with its non-US foreign affiliate, the issuer of this report.

In the UK this report may only be distributed to persons of a kind described in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001. The protections afforded by the UK regulatory regime are available only to those dealing with a representative of HSBC Bank plc in the UK. In Singapore, this publication is distributed by The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch for the general information of institutional investors or other persons specified in Sections 274 and 304 of the Securities and Futures Act (Chapter 289) ("SFA") and accredited investors and other persons in accordance with the conditions specified in Sections 275 and 305 of the SFA. This publication is not a prospectus as defined in the SFA. It may not be further distributed in whole or in part for any purpose. The Hongkong and Shanghai Banking Corporation Limited Singapore Branch is regulated by the Monetary Authority of Singapore. In Australia, this publication has been distributed by The Hongkong and Shanghai Banking Corporation Limited (ABN 65 117 925 970, AFSL 301737) for the general information of its "wholesale" customers (as defined in the Corporations Act 2001). Where distributed to retail customers, this research is distributed by HSBC Bank Australia Limited (AFSL No. 232595). These respective entities make no representations that the products or services mentioned in this document are available to persons in Australia or are necessarily suitable for any particular person or appropriate in accordance with local law. No consideration has been given to the particular investment objectives, financial situation or particular needs of any recipient.

In Japan, this publication has been distributed by HSBC Securities (Japan) Limited. In Hong Kong, this document has been distributed by The Hongkong and Shanghai Banking Corporation Limited in the conduct of its Hong Kong regulated business for the information of its institutional and professional customers; it is not intended for and should not be distributed to retail customers in Hong Kong. The Hongkong and Shanghai Banking Corporation Limited makes no representations that the products or services mentioned in this document are available to persons in Hong Kong or are necessarily suitable for any particular person or appropriate in accordance with local law. All inquiries by such recipients must be directed to The Hongkong and Shanghai Banking Corporation Limited. In Korea, this publication is distributed by The Hongkong and Shanghai Banking Corporation Limited, Seoul Securities Branch ("HBAP SLS") for the general information of professional investors specified in Article 9 of the Financial Investment Services and Capital Markets Act ("FSCMA"). This publication is not a prospectus as defined in the FSCMA. It may not be further distributed in whole or in part for any purpose. HBAP SLS is regulated by the Financial Services Commission and the Financial Supervisory Service of Korea.

© Copyright. HSBC Securities and Capital Markets (India) Private Limited 2010, ALL RIGHTS RESERVED. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, on any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of HSBC Securities and Capital Markets (India) Private Limited. MICA (P) 177/08/2009